Article Text

PDF

Social factors and chronic diseases
O5-2.3 A new multiple sclerosis prevalence study in Aberdeen city, Orkney and Shetland
  1. E Visser1,
  2. K Wilde2,
  3. K K Yong3,
  4. J F Wilson4,
  5. C Counsell1
  1. 1Population Health, College of Life Sciences & Medicine, Division of Applied Health Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
  2. 2Directorate of Information Technology, University of Aberdeen, Foresterhill, Aberdeen, UK
  3. 3Aberdeen Royal Infirmary, NHS Grampian, Foresterhill, Aberdeen, UK
  4. 4Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK

Abstract

Background Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system of unknown aetiology. It is the commonest cause of chronic neurological disability in young people. The disease is more common in those of Northern European origin and the highest prevalence rates in the world have been recorded in the North of Scotland. However, there has been no prevalence study in this area since 1983.

Aims We undertook a new prevalence study of MS in Aberdeen City, and the Orkney and Shetland islands to: calculate age-gender specific prevalence rates; compare variations in age-gender standardised prevalence rates between areas and over time; calculate prevalence rates by MS sub-type, diagnostic criteria and to gather information on disability status.

Methods We used GP-practice records, hospital records and laboratory data for case ascertainment of patients alive and resident in the study area on prevalence day (24 September 2009), verified their diagnoses by reviewing medical records and included participants according to the research diagnostic criteria of Poser, McDonald 2001 and McDonald 2005. Information on disability was gathered from medical records and patient questionnaires. Prevalence rates and CIs were calculated assuming a Poisson distribution and standardised against the Scottish population (30 June 2009).

Results We found 590 patients in the combined study area (Aberdeen 442, Orkney 82, Shetland 66). Mean age was 52 years (SD ±13), and the age-standardised male to female ratio was 1:2 (95% CI 1.6 to 2.1). The standardised prevalence rate for the combined study area was 257 per 100 000 (95% CI 236 to 277), in Aberdeen City 237 per 100 000 (95% CI 214 to 257), in Orkney 421 per 100 000 (95% CI 329 to 512) and in Shetland 305 per 100 000 (95% CI 231 to 379). There were significant differences between Orkney and the other areas, and significant differences in the prevalence rates over time in Orkney and Shetland, but not for Aberdeen City. A relapse-remitting disease pattern was recorded in 50% of participants and 45% of patients had significant disability levels.

Conclusion The prevalence of MS has increased in the North of Scotland over the last 30 years, which may reflect methodological differences in studies over time, improved diagnostic methods, or a true increase in prevalence due to improved survival, higher incidence rates or as a result of migration. Currently Orkney has the highest MS prevalence rate in the world. New disability data could be used to plan health services in these communities.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.